N/A
N=104
An RCT of a Telemedicine Intervention for Hypokinetic Dysarthria in PD
Parkinson's Disease
Bottom Line
View on ClinicalTrials.gov: NCT04617496 ↗Enrolled (actual)
104
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: Change in Speech Intelligibility at 6 Months — 0.25; -4.78 score on a scale — p=0.13
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Combined speech and exercise intervention (Behavioral); Health education (Behavioral)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Nov 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Speech Intelligibility at 6 Months |
0.25; -4.78 | 0.13 |
| SECONDARY Change in in Self-perceived Communication Ability Measured Via the Communication Effectiveness Index (CETI-M) at 6 Months |
6.8; -6.4 | <0.01 sig |
Summary
Nearly 90% of people with Parkinson's disease have speech and voice disorders that negatively impact their ability to communicate effectively in daily life. This study will test the hypothesis that a combined speech and exercise intervention will improve speech intelligibility in people with Parkinson's disease and speech impairment. This approach would offer an affordable way to continue to both instruct and encourage training by Veterans virtually indefinitely through the remote access technology. These findings may help VA clinicians provide optimal care for the many Veterans with Parkinson's disease and speech impairment.
Eligibility Criteria
Inclusion Criteria
- Physician diagnosis of idiopathic Parkinson's disease (PD)
- At least 2 of the 3 cardinal signs of PD (resting tremor, rigidity, bradykinesia)
- Response to dopaminergic medication
- Hypokinetic dysarthria
Exclusion Criteria
- Angina pectoris
- History of myocardial infarction (MI) within 6 months
- History of ventricular dysrhythmia requiring current therapy
Data sourced from ClinicalTrials.gov (NCT04617496). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.